News

As part of its plans, the company has decided to focus its Osaka plant to become a specialty manufacturing site for prostate and breast cancer drug Leuplin/Lupron (leuprorelin).

Featuring contributions from leading analysts, professional representatives and patient groups, the event combined theexperience and views of Merck Consumer Health’s senior management team with external perspectives on the

Alimera has also agreed to issue an additional 124.378 shares of preferred stock as a subscription premium. The preferred stock will be convertible into an aggregate of 8,416,251

The licence will enable other companies and organisations to re-formulate and manufacture specially designed LPV/r and r paediatric treatments for distribution in low- and middle-income countries where 99%

The sBLA was based on an international, multi-center, double-blind, randomized, placebo-controlled Phase III trial which included around 250 adult patients with upper limb spasticity. The trial, which was

As part of the deal, UCB will manufacture and supply the product for commercialisation and Daiichi will manage the distribution and book sales. The deal, which is subject

Under the five-year deal, Cancer Research UK researchers will have access to around two million molecules in AstraZeneca’s compound library, in addition to screening tools at the facility

The accelerated review procedure is granted infrequently by the EMA and so far it has not been awarded in the cardiovascular area. The decision on European Union (EU)

Actavis has begun shipping the product and, under applicable Hatch Waxman rules, is entitled to 180 days of marketing exclusivity. Intuniv is a prescription medicine used to treat